Differences in the regulation of [3H]idazoxan and [3H]yohimbine binding sites in the rabbit.

Eur J Pharmacol

Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow, Scotland.

Published: February 1990

In vitro studies suggest that [3H]yohimbine binds to alpha 2-adrenoceptors while [3H]idazoxan binds preferentially at a non-adrenergic site. In order to compare in vitro with in vivo effects male New Zealand White rabbits received the following treatments: 5 days idazoxan 1.1 mg/kg per h, 10 days noradrenaline 46 micrograms/kg per h (intravenous infusion), 21 days amitriptyline 30 mg/kg per day (intraperitoneally) or vehicle. The effect of these treatments on the number of [3H]yohimbine and [3H]idazoxan binding sites was examined. Ten days noradrenaline infusion and 21 days amitripytyline treatment significantly reduced [3H]yohimbine binding in kidney and hindbrain membranes respectively, but had no significant effect on [3H]idazoxan binding. Five days idazoxan infusion significantly increased [3H]yohimbine binding in the forebrain, while a significant reduction in [3H]idazoxan binding sites in the kidney was observed. Thus differential regulation of the two binding sites was observed in vivo. These alterations in binding site number are consistent with the differing affinities of noradrenaline and idazoxan for the [3H]yohimbine and [3H]idazoxan binding sites previously observed in vitro and support the hypothesis that in the rabbit idazoxan binds preferentially at non-adrenergic sites while yohimbine binds to an alpha 2-adrenergic site. The idazoxan site may be an imidazoline type of receptor but further work, including functional studies, is required to substantiate this.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0014-2999(90)90024-zDOI Listing

Publication Analysis

Top Keywords

binding sites
20
[3h]idazoxan binding
16
[3h]yohimbine binding
12
binding
9
binds alpha
8
binds preferentially
8
preferentially non-adrenergic
8
days idazoxan
8
days noradrenaline
8
infusion days
8

Similar Publications

Shotgun and targeted proteomics of Mycolicibacterium smegmatis highlight the role of arginine phosphorylation in the functional adaptation to its environment.

J Proteomics

January 2025

State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Institute of Lifeomics, Beijing 102206, China. Electronic address:

Although the phosphorylation of serine (S), threonine (T), and tyrosine (Y) is well-established, arginine phosphorylation (pR) has recently garnered significant attention due to its crucial role in bacteria pathogenicity and stress response. Mycolicibacterium smegmatis, a nonpathogenic surrogate of Mycobacterium tuberculosis, serves as a model for studying mycobacterial pathogenesis. A recent proteomics study identified six pR proteins in M.

View Article and Find Full Text PDF

Withania somnifera-derived phytochemicals as Bcl-B inhibitors in cancer therapy: A computational approach from byte to bench to bedside.

Biochem Biophys Res Commun

January 2025

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida, India. Electronic address:

Cancer is the second foremost cause of fatalities associated with non-communicable diseases across the globe, affecting multiple organs and often necessitating costly treatments with adverse side effects. Apoptosis, the body's natural cell death process, plays a crucial role in the prevention of cancer, but it's often disrupted in cancer cells, allowing uncontrolled proliferation. Restoring apoptosis in cancer cells is one of the promising therapeutic strategies to curb tumor growth and enhance clinical outcomes.

View Article and Find Full Text PDF

Label-free electrochemical immunosensors based on Cu-Ni metal-organic framework and carbon nanotube composite for carcinoembryonic antigen detection.

Bioelectrochemistry

January 2025

Hubei Key Laboratory of Diabetes and Angiopathy, Xianning 437100 PR China; School of Pharmacy, Hubei University of Science and Technology, Xianning 437100 PR China. Electronic address:

Monitoring cancer biomarkers is of great significance in clinical diagnosis. In this work, a label-free MWCNTs-COOH/CuNi-BTC/FTO electrochemical immunosensor was developed to quantitatively detect carcinoembryonic antigen (CEA). The bimetallic CuNi-BTC showed enhanced current than singe Ni-BTC, and the addition of the MWCNTs-COOH increased the conductivity and further amplified the current signal.

View Article and Find Full Text PDF

The Small Cycloamylose (CA15) Synthesizing Properties of 4-α-Glucanotransferase from Hyperthermophilic Archaeon with Its Distinct Disproportionation Activity.

J Agric Food Chem

January 2025

Department of Food Science and Biotechnology, Graduate School of Biotechnology and Institute of Life Science and Resources, Kyung Hee University, Yongin 17104, Republic of Korea.

4-α-Glucanotransferase (4-α-GTase, EC 2.4.1.

View Article and Find Full Text PDF

Allosteric site engagement and cooperativity mechanism by PHI1 for BRAF kinase inhibition.

Int J Biol Macromol

January 2025

School of Physics and Electronics, Shandong Normal University, Jinan 250014, China. Electronic address:

With the ability to reveal allosteric sites, Ponatinib and Ponatinib Hybrid Inhibitor 1 (PHI1) are novel inhibitors of BRAF, a potent oncogene that activates the MAPK pathway. PHI1 also exhibits unique positive cooperativity, with enhanced inhibition on the other monomer when one monomer of the BRAF dimer bound to an inhibitor. The abovementioned properties lack rigorous theoretical verification, so this study compared the interaction mechanisms of four inhibitor types and explored the source of the cooperativity of PHI1 via various computational methods.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!